Jounce Therapeutics, Inc. (NASDAQ:JNCE)‘s stock had its “outperform” rating reiterated by stock analysts at Robert W. Baird in a note issued to investors on Monday. They presently have a $30.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 94.81% from the stock’s current price.
JNCE has been the subject of several other reports. Zacks Investment Research upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a report on Friday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Jounce Therapeutics in a report on Friday, June 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Jounce Therapeutics currently has an average rating of “Buy” and a consensus price target of $23.67.
Shares of Jounce Therapeutics (NASDAQ:JNCE) traded up 0.72% on Monday, hitting $15.40. The company had a trading volume of 211,231 shares. Jounce Therapeutics has a 1-year low of $11.05 and a 1-year high of $29.29. The firm has a market capitalization of $495.17 million and a price-to-earnings ratio of 570.37. The company has a 50 day moving average price of $15.04 and a 200 day moving average price of $18.09.
Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $20.29 million during the quarter, compared to the consensus estimate of $19.94 million. During the same quarter in the prior year, the company earned ($7.23) earnings per share. On average, equities analysts forecast that Jounce Therapeutics will post ($0.62) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the company. Redmile Group LLC boosted its stake in shares of Jounce Therapeutics by 2.2% in the 2nd quarter. Redmile Group LLC now owns 1,138,370 shares of the company’s stock worth $15,971,000 after buying an additional 24,210 shares during the last quarter. State Street Corp lifted its position in Jounce Therapeutics by 120.6% during the second quarter. State Street Corp now owns 100,233 shares of the company’s stock valued at $1,409,000 after purchasing an additional 54,803 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Jounce Therapeutics by 465.7% during the second quarter. Goldman Sachs Group Inc. now owns 69,648 shares of the company’s stock valued at $977,000 after purchasing an additional 57,336 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in Jounce Therapeutics during the second quarter valued at $747,000. Finally, Teachers Retirement System of The State of Kentucky lifted its position in Jounce Therapeutics by 180.0% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 12,600 shares of the company’s stock valued at $177,000 after purchasing an additional 8,100 shares in the last quarter. Hedge funds and other institutional investors own 43.50% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.